Carmantadine Explained
| Cas Number: | 38081-67-3 |
| Pubchem: | 37906 |
| Chemspiderid: | 34751 |
| Unii: | 6EK3N87MMH |
| Kegg: | D03407 |
| Chembl: | 2106463 |
| Synonyms: | SCH-15427; NSC-172618 |
| Iupac Name: | 1-(1-adamantyl)azetidine-2-carboxylic acid |
| C: | 14 |
| H: | 21 |
| N: | 1 |
| O: | 2 |
| Smiles: | C1CN(C1C(=O)O)C23CC4CC(C2)CC(C4)C3 |
| Stdinchi: | 1S/C14H21NO2/c16-13(17)12-1-2-15(12)14-6-9-3-10(7-14)5-11(4-9)8-14/h9-12H,1-8H2,(H,16,17) |
| Stdinchikey: | VPBLOJFGPORKQA-UHFFFAOYSA-N |
Carmantadine (; developmental code name SCH-15427) is an antiparkinsonian agent of the adamantane group that was never marketed.[1] [2] [3] It is structurally related to amantadine and shares some of its pharmacological actions.[4] Another related drug is dopamantine. Carmantadine was first described by 1972 and is said to have reached early clinical trials.
Notes and References
- Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . Springer US . 2014 . 978-1-4757-2085-3 . 13 September 2024 . 13.
- Barnett A, Goldstein J, Taber R, Fiedler E . Pharmacology of Dopamantine and Carmantadine, 2 Potential Antiparkinson Agents . January 1974 . Pharmacologist . 16 . 2 . 205– .
- Goldstein J, Barnett A . Antagonism of electrically-induced heart-turning (HT) following intracaudate administration of dopamine (DA), amantadine (AM), apomorphine (APO), dopamantine and carmantadine . January 1974 . Pharmacologist . 16 . 2 . 206 .
- Book: Vernier VG, du Pont E . Heinzelman RV . Annual Reports in Medicinal Chemistry . Chapter 3. Antiparkinsonism Drugs . Elsevier . 9 . 1974 . 978-0-12-040509-1 . 10.1016/s0065-7743(08)61424-4 . 19–26 . https://books.google.com/books?id=rZBH1_7Tx6UC&pg=PA21 . Carmantadine (VII, Sch 151427) is structurally related to amantadine33. It shares some of its pharmacological actions, was effective in a head—turning test34 and is in early clinical trials..
